|
Molecular Basis of ALK Inhibition Resistance in High-risk Neuroblastoma |
Dana-Farber Cancer Institute |
Northwestern Mutual Foundation |
|
Genetically Engineered T Cells as Therapy for Pediatric Glioma |
Baylor College of Medicine |
Northwestern Mutual Foundation |
|
Single-cell RNA-seq Profiling of Transcriptional Transition States During Human Retinoblastoma |
Children’s Hospital Los Angeles |
Northwestern Mutual Foundation |
|
CAMKV as a Target for Immunotherapy in MYCN-Amplified Neuroblastoma |
Children’s Hospital of Philadelphia |
Northwestern Mutual Foundation |
|
Small Molecule Inhibitors of ERG for Pediatric Leukemia and Sarcoma |
University of Virginia, School of Medicine |
I Care I Cure, The Brian Morden Foundation |
|
Small Molecule Inhibitors of ERG for Pediatric Leukemia and Sarcoma |
University of Virginia, School of Medicine |
I Care I Cure, The Brian Morden Foundation |
|
Enhancing Effectiveness of Immune Checkpoint Therapy in Neuroblastoma |
Children’s Hospital Los Angeles |
Northwestern Mutual Foundation |
|
Pharmacogenomics and Drug Screening Lead to a Novel Targeted Therapy with Potent and Specific Activity Against Mouse Models of MYCN-amplified Neuroblastoma |
Virginia Commonwealth University |
Cure4Cam Childhood Cancer Foundation, I Care I Cure |
|
Pharmacogenomics and Drug Screening Lead to a Novel Targeted Therapy with Potent and Specific Activity Against Mouse Models of MYCN-amplified Neuroblastoma |
Virginia Commonwealth University |
Cure4Cam Childhood Cancer Foundation, I Care I Cure |
|
Preclinical Development of Atr Inhibitor VE-822, Delivered Systemically in Nanoparticles, for Medulloblastoma Therapy |
University of North Carolina |
Cure4Cam Childhood Cancer Foundation, I Care I Cure |
